Wednesday, April 15, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 15, 2026
FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
background ▾
- •FDA approval of Foundayo includes explicit safety reservations and a demand for additional post-market safety data on multiple 'unexpected serious' adverse events, indicating conditional/contingent approval rather than clean clearance
- •This represents a significant regulatory risk to Eli Lilly's obesity franchise at a critical commercial juncture and may constrain market uptake, physician prescribing, or payer coverage pending safety resolution
- •Monitor for post-marketing safety study results, potential label changes, and competitive positioning shifts in the oral GLP-1 market as safety data emerges
Eli LillyFoundayo
→ Read original articlePolicy•Fierce Biotech•Apr 15, 2026
FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
background ▾
- •The plausible mechanism framework is not an exclusive pathway for individualized therapies; its regulatory principles may apply to other modalities, though the FDA retains discretion in application
- •The framework sets a demanding threshold: rare disease, deep mechanistic understanding, large effect sizes, and genuine RCT infeasibility—creating risk that some developers will face inconsistent regulatory interpretation
- •Monitor how FDA applies plausible mechanism principles to non-bespoke gene therapies and other modalities; uniQure's ongoing AMT-130 strategy and potential resubmission will be a key test case for consistency
uniQureAMT-130
→ Read original articlePolicy•STAT News•Apr 15, 2026
Opinion: Hosting the ‘intellectual wrestling match’ between MAHA, public health
background ▾
- •A new media platform is attempting to bridge the deep divide between MAHA/anti-vaccine movements and mainstream public health—a schism likely to shape regulatory and policy decisions affecting pharma and vaccines going forward
Policy•STAT News•Apr 15, 2026
Opinion: Medical schools must continue to teach students about structural barriers to care
background ▾
- •LCME removed explicit language from Standard 7.6 encouraging teaching about structural barriers to care, making this content easier for medical schools to deprioritize
- •The removal occurred under political pressure and reflects a retreat from health equity education requirements established in 2015
- •Monitor whether medical schools actually reduce coverage of social determinants of health and whether accreditation bodies clarify or reverse this policy decision
Policy•KFF•Apr 14, 2026
Implementing Medicaid Work Requirements: Lessons from Unwinding
background ▾
- •Medicaid work requirements mandate takes effect January 1, 2027, affecting ACA expansion enrollees across most states plus Georgia and Wisconsin, requiring substantial state operational and systems readiness within ~24 months
- •Multi-modal, coordinated outreach strategies and strong partnerships with MCOs, community health centers, and community-based organizations proved critical to engagement during unwinding and will be essential for work requirement implementation
- •State variation in implementation outcomes is likely; success depends on adequacy of staff training, system upgrades, contact information accuracy, and effectiveness of feedback loops—all factors that showed significant state-to-state variation during unwinding
Market Access
Market Access•Fierce Biotech•Apr 14, 2026
Cell therapy biotech Obsidian leverages Galera reverse merger to go public
background ▾
- •OBX-115 has FDA fast-track and regenerative medicine advanced therapy designations for checkpoint inhibitor-resistant melanoma, with phase 2 data expected by end of 2024 and NSCLC phase 1 readout anticipated in H1 2027
- •The $350 million funding round includes major institutional investors (Balyasny, Redmile, RA Capital) alongside existing backers, indicating institutional confidence in the TIL platform despite historical limitations in the space
- •Monitor melanoma trial topline results (end of 2024) and NSCLC phase 1 progression (H1 2027) to assess whether Obsidian's engineered TIL approach overcomes prior toxicity and efficacy barriers that limited competitor development
Obsidian TherapeuticsGalera TherapeuticsBalyasny Asset ManagementOBX-115avasopasem
→ Read original articleMarket Access•Fierce Biotech•Apr 14, 2026
Stryker makes a buy as Avanos Medical to go private in a spate of medtech M&A deals
background ▾
- •Stryker's acquisition of Amplitude Vascular strengthens its peripheral vascular portfolio with IVL balloon catheter technology for treating calcified arterial disease—a significant unmet clinical need
- •Avanos Medical's 72% premium buyout at $25/share signals investor confidence in non-opioid pain management and enteral feeding solutions despite public market challenges
StrykerAmplitude Vascular SystemsAvanos Medical
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 14, 2026
Travere Therapeutics gains FDA approval for sparsentan in FSGS
background ▾
- •Filspari is now the first and only FDA-approved therapy for FSGS, establishing market exclusivity in a previously untreated rare kidney disease segment with ~100,000+ US patients
- •The approval was granted despite the pivotal trial missing its primary endpoint overall, suggesting FDA accepted the compelling efficacy signal in the non-nephrotic subgroup as clinically meaningful
- •Revenue opportunity is substantial given rare disease designation, unmet medical need, and dual-indication potential (FSGS + IgAN), but payer acceptance and pricing negotiation will be critical to commercialization success
Travere TherapeuticsFilsparisparsentan
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 13, 2026
AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid
background ▾
- •AbbVie is executing an aggressive pipeline restocking strategy following Humira's patent cliff, with this Haisco deal complementing a $5.6bn RemeGen oncology licensing agreement signed in January 2026.
- •Chinese biopharma licensing has become mainstream for large pharma, with 28% of innovator drugs licensed from China in 2024, driven by cost efficiency and emerging first/best-in-class potential in oncology and immunology.
- •Monitor clinical progression of HSK-55718 and other undisclosed assets in Haisco's pain portfolio; early clinical readouts will signal whether this bet addresses AbbVie's significant revenue gap as Humira faces $21bn+ in annual sales losses.
AbbVieHaiscoHumira (adalimumab)Skyrizi (risankizumab)Rinvoq (upadacitinib)
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 15, 2026
Adcendo secures $75m in Series C funding for ADC development
background ▾
- •Adcendo has now raised approximately $210 million (Series B: $135m in November 2024, Series C: $75m) within six months, indicating strong investor confidence in its ADC platform despite competitive space
- •Three programs are advancing with near-term catalysts: ADCE-T02 cohort expansion, ADCE-D01 dose escalation in soft tissue sarcoma, and ADCE-B05 pre-clinical transition—watch for 2025 clinical data readouts that could validate differentiation claims
AdcendoJeito CapitalVida VenturesADCE-T02ADCE-D01ADCE-B05
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 14, 2026
Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
background ▾
- •Kazia acquired an AI-integrated epigenetic platform targeting SETDB1 to address immune checkpoint inhibitor resistance, representing entry into a novel mechanism class.
- •The deal includes a lead bicyclic peptide candidate (MSETC) plus a pipeline of follow-on molecules, though all appear to be in preclinical stage.
- •Watch for MSETC IND filing timeline and clinical trial initiation; monitor whether Kazia's multi-layered oncology strategy (epigenetics, PI3K/Akt/mTOR, PD-L1) can recover from paxalisib's recent failure.
Kazia TherapeuticsQIMR BerghoferpaxalisibMSETC
→ Read original articleClinical Trials•STAT News•Apr 14, 2026
For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option
background ▾
- •Daraxonrasib demonstrated clinically meaningful survival benefit (13.2 vs 6.7 months) in Phase 3 RASolute 302 for second-line advanced pancreatic cancer, with expert consensus suggesting approval is likely
- •First-line use in earlier disease stages may yield even greater survival benefits, as evidenced by individual patient experiences, potentially positioning this as transformative for KRAS-mutant pancreatic cancer treatment
- •Monitor for FDA regulatory decision timeline, companion diagnostic requirements (genetic profiling), and potential label expansion to first-line setting based on ongoing trial data
Revolution Medicinesdaraxonrasib
→ Read original articleClinical Trials•Endpoints News•Apr 14, 2026
Parker Institute doubles down on cancer vaccines as part of ongoing reboot
background ▾
- •Parker Institute is expanding cancer vaccine investment while industry momentum in mRNA vaccines is declining due to political and commercial pressures
- •The decision reflects confidence in mRNA's oncology applications despite broader skepticism in the sector
- •Clinical and commercial success of mRNA cancer vaccines remains unproven at scale, with multiple competitors pursuing similar strategies
Parker Institute
→ Read original article